In this video we discuss 3-year results of the COMBI-d trial, which studied dabrafenib and trametinib in patients with unresectable or metastatic BRAF-mutated melanoma.
Caroline Robert, MD, PhD
Advertisement
Articles by Caroline Robert, MD, PhD
Advertisement
Latest Updated Articles
BRAF, MEK Inhibition Shows Strong Long-Term Survival Benefit in MelanomaPublished: June 22nd 2016 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
CRT Does Not Improve RFS/OS, Confers High-Grade Toxicity in Cervical Cancer
3
Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era
4
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
5
